Monday, October 21, 2013

(LML) MB patients without clear treatment status and chronic ENL

Leprosy Mailing List – October 21,  2013 

Ref.:    (LML) MB patients without clear treatment status and chronic ENL

From:  Jaison Barreto, Bauru, São Paulo, Brazil


Dear Pieter,

 

About this cases of "eternal ENL", the view of Dr. Walker and Dr. van Brakel are well stated.

 

I have seen several cases of recurrent ENL in the field and inside our Institute. There are 3 conditions that must be observed by the physician: 

1.     In some instances, as posted by Steve, the affected patient still presents active lesions, usually lepromas, and when we take a smear FROM THE LEPROMAS (not only from index points), there are still viable (not fragmented) bacilli. In this cases, however, not always we see growth of M. leprae in mouse foot pads. I think the cause of this paradox is because the tissue of old leproma still has a huge amount of clofazimine, which is bacteriostatic.

2.    Some patients have infections or parasitosis, or sometimes not controlled diabetes. All we know that not specific inflammations or stress can stimulate immune system, and be the trigger of a immunological hypersensitivity.

3.    I have seen that as many as 50% of patients who suffer from recurrent ENL still have contact with MB not diagnosed, when I call the household contacts and evaluate them. As many as 80% were not, indeed, evaluated, i.e., had previous dermatological and neurological examination. Most do not live at the same house, and often do not present clearly visible patches. Many (mainly grandfather/grandmother) have previous misdiagnosis of sinusitis, rheumatism, circulatory diseases, connective tissue disease, and other conditions.

 

So, once LL leprosy is very difficult to diagnose, and grandfather/grandmother/brothers are not commonly called to be evaluated when they do not live with the patient, I always call all the family when I find "uncontrollable reactions". I have seen that several "uncontrolled" Type 1 or Type 2 reactions become controllable after the beginning of treatment of ALL affected persons of the family. Leprosy MUST BE SEEN AS A DISEASE INSIDE THE FAMILY.

 

Finally, and interestingly, we all know that when an individual is exposed to antigens which he was previously sensibilized, the natural response is hypersensitivity: PPD reaction is high in active tuberculosis, Montenegro reaction is high in cutaneous leishmaniasis, rheumatic fever can occur just after the single contact between mucosa and Streptococcus, etc. Why this situation could not possible for leprosy? If we agree that antibody production to PGL-1 can occur just because there was a single contact between M. leprae and nasal mucosa, though this does not mean disease, why a hypersensitivity reaction cannot?

 

Best regards,

 

Jaison  

     


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

(LML) MB patients without clear treatment status and chronic EN

Leprosy Mailing List – October 21,  2013 

Ref.:    (LML) MB patients without clear treatment status and chronic ENL

From:  Maneesha Godbole, Andhra Pradesh, India


Dear Dr. Schreuder,

 

I would like to refer to the letter of Prof. José Augusto da Costa Nery of 17 October 2013.

 

If it is possible to obtain information about their treatment status from the state that they have migrated in from, it would be excellent. This is possible if the records are maintained and there exists a good communication system. I have no idea how it would be in your country. In India, it would be possible if the patient migrates in from within the same state, but difficult if from another state. If the patient gives the history of having completed treatment recently, then of course it would take time for the BI to come down.

 

However, if the history is very unreliable, it would be safer to restart and complete a full course of MDT, not only for the patient's benefit, but also in the  interest of the community, to prevent transmission.

 

The Type II reaction can be managed with Thalidomide and steroids as required. Starting the patient on high dose of clofazimine would reduce the frequency and severity of the episodes. It can be given in the dose of 100 mg 3 times a day for 3 months, then 100 mg 2 times a day for 3 months, followed by 100 mg once a day for 3 months and then reduce to 50 mg daily.

 

With best wishes,


Dr.Maneesha Godbole
India


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

Sunday, October 20, 2013

(LML) MB patients without clear treatment status and chronic ENL

Leprosy Mailing List – October 20 ,  2013 

Ref.:     (LML) MB patients without clear treatment status and chronic ENL

From:   Wim van Brakel, Amsterdam, the Netherlands


 

Dear Pieter,

 

Thanks for the interesting question raised by Dr. José Augusto in LML of October 20, 2013.

 

The difficulty seems to be the reliability of the history of treatment. I'm inclined to trust (former) patients regarding what they tell me. It may take time though to win their trust and to explain that you need this information to decide on the best course of treatment for them. If there is doubt, I would give another course of MB MDT. This is particularly useful if patients will remain under your or someone else's medical supervision during that time. 

 

In my view it is not useful to restart MDT in the case of post-MDT ENL reactions, if a full course of MDT has been completed. The reason that the incidence of ENL reactions increases after release from MDT is the loss of the anti-inflammatory effect of clofazimine. A reaction is not a sign of bacterial activity, as I'm sure you know, at least not in the first few years after MDT. 

 

Clofazimine has a definite role in post-MDT ENL reaction management, particularly in patients with repeated episodes of reaction. Thalidomide is very effective, but not necessary unless reactions are very severe or insufficiently treated with clofazimine and corticosteroids. 

 

With kind regards, 

 

Wim van Brakel, MD MSc PhD

Technical Advisor NLR 

 

w.v.brakel@kit.nl

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

(LML) MB patients without clear treatment status and chronic ENL

Leprosy Mailing List – October 20,  2013 

Ref.:    (LML) MB patients without clear treatment status and chronic ENL

From:  Stephen Walker, London, UK


 

 

Dear Pieter

 

 

I would like to refer to the letter of José Augusto of October 17, 2013 and thanking him for sharing this scenario with us.

 

Such decisions need to be made on an individual basis for each patient given the information available and its reliability. It is also important to ensure that they are adherent to their ENL treatment and have no underlying intercurrent medical problems driving the reaction.

 

I think there are good reasons for instituting MB MDT in these patients:

1. It ensures that one can be confident they have been adequately treated with respect to infection.

2. There may be some anti-ENL benefit from clofazimine

3. MB MDT was previously given for longer than 12 months to all patients and the Global Strategy allows for the extension of MB treatment in highly smear positive individuals beyond 12 months. Therefore recognising that in these individuals there are benefits to extending treatment. In Section 5.2 Enhanced Global Strategy 2011-15: "Rarely, it may be considered advisable to treat a patient with a high Bacterial Index (BI) for more than 12 months. This decision may only be taken by specialists at referral units after careful consideration of the clinical and bacteriological evidence."

 

Having said all that I am not aware of any evidence to suggest that this approach will shorten the duration or reduce severity of the ENL in the situation you describe.

 

The LML is a good forum to get other views and via the ENLIST LinkedIn board/email list.

 

 

Best wishes,

 

Steve

   

Dr Stephen Walker PhD MRCP(UK) DTM&H
Consultant Dermatologist and Clinical Research Fellow
Department of Clinical Research 
Faculty of Infectious and Tropical Diseases
London School of Hygiene and Tropical Medicine
Keppel St
London
WC1E 7HT
44
20 7612 7863
44 7847 187831


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

Thursday, October 17, 2013

(LML) MB patients without clear treatment status and chronic ENL

Leprosy Mailing List – October 17,  2013 

Ref.:    (LML) MB patients without clear treatment status and chronic ENL

From:  José Augusto, Rio de Janeiro, Brazil


Dear Pieter,

We received some MB patients from other states without reliable information about their treatment history and if they received  the full course of MDT. Most of these patients have still a high BI. These patients have maintained reactional episodes of ENL which are difficult to control.

Do you think these patients should be restated MDT to ensure a full course of MDT while we are trying to reduce these episodes of type II reaction? As reaction treatment usually  thalidomide is given together with or without prednisone and pentoxifylline.

What is the advice of LML readers regarding this same situation (to restart a full course of MDT or not) in other countries?

 

Best regards,

 


Dr. José Augusto da Costa Nery

Ambulatório Souza Araújo

Laboratório de Hanseníase

Instituto Oswaldo Cruz - Fiocruz

Av. Brasil 4365, Manguinhos, Rio de Janeiro - RJ CEP 21040-360

Tel. (21)2562-1588

neryjac@ioc.fiocruz.br

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

Wednesday, October 16, 2013

(LML) The place of leprosy in present day national health systems

Leprosy Mailing List – October 16,  2013 

Ref.:    (LML) The place of leprosy in present day national health systems

From:  Joseph Kawuma, Kampala, Uganda


Dear Pieter,

 

Thank you for inviting me. By attached file you will find my Power-Point presentation “LEPROSY IN A CHANGE CONTEXT. The place of leprosy in present day national health systems” as given at the International Leprosy Congress, Brussels, September 2013. Of course the PP cannot contain all that I said and what was discussed during the presentation.

 

Best regards,

 

Herman-Joseph Kawuma

GLRA, Uganda

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

Thursday, October 10, 2013

(LML) Report on ILC pre-congress workshop 'Community-bases approaches to patient detection and improving leprosy services` 16.09.2013

Leprosy Mailing List – October 10,  2013 

Ref.:    (LML)  Report on ILC pre-congress workshop 'Community-bases approaches to patient detection and improving leprosy services` 16.09.2013

From:  Ernst Hisch, Wuerzburg, Germany


Dear Dr. Schreuder,

 

Please fin attached the report on the workshop above for LML distribution.

The workshop was –despite of short notice- well attended and well received by the audience. We are working on a follow up.

 

Best wishes,

 

Ernst Hisch

Teamleader Program Development and Research

Deutsche Lepra- und Tuberkulosehilfe e.V.

German Leprosy and TB Relief Association

Marianhill Strasse 1c

97074 Wuerzburg

Germany

Email: ernst hisch@dahw.de

Tel. 0049-(0)931-7948-120


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com